
Nektar Therapeutics Reports Durable Results for Rezpegaldesleukin
Patients with alopecia areata and atopic dermatitis showed sustained clinical improvement following treatment with rezpegaldesleukin, according to one-year data presented at the EADV Congress 2026. The findings highlight the drug’s potential as a disease-modifying therapy by targeting regulatory T cells to address immune dysregulation.


























